Navigation Links
Calabar AB Today Announced New Financing for Continuation of the Phase II Program in Patients With Dry Mouth

GOTEBORG, Sweden, September 1 /PRNewswire/ -- Calabar AB, a privately held pharmaceutical company developing therapies for treating dry mouth, today announced a EUR 350,000 equity financing from the investment company Karolinska Development AB. The financing will take Calabar's product through a phase II study with repeated dosing. "We believe the unique local action of the drug on the minor glands will lead to improved outcomes in patients with dry mouth and we look forward to its continued development," remarked VP Business Development, Fredrik Rook of Calabar AB. "Dry mouth is affecting millions of people every day and there is a great unmet need for new drugs in this area."

The active drug, physostigmine, a cholinesterase inhibitor, targets the minor salivary glands with a direct local action, inducing a more lubricating saliva. In previous phase II studies with single dosing, the locally administered drug proved to significantly increase the salivary flow in patients suffering from dry mouth.

"This will take treatment of dry mouth symptoms to a new level," concludes Mr. Rook.

About Calabar

Calabar AB is a privately-held company committed to developing a pharmaceutical product addressing the great unmet needs of xerostomia "dry mouth". The company develops locally administered formulations of the cholinesterase inhibitor physostigmine, which has been shown to effectively increase salivary flow. Unlike systemically administered drugs, the local route of administration significantly limits adverse events. The company is part of the Karolinska Development AB portfolio. For more information, please visit

Investor and Media Contact

Fredrik Rook,

+46-8-524-860-38, .

Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. TorreyPines Therapeutics to Host Webinar at 11 a.m. EDT Today on the Opportunity for Treating Chronic Pain, Migraine and Muscle Spasticity Through Inhibition of Neurotransmitter Glutamate
2. Phase 1 & 2 Data of Perifosine (KRX-0401) in Patients with Advanced Renal Cell Carcinoma Presented Today at the 25th Annual Chemotherapy Foundation Symposium
3. 454 Sequencing(TM) in Science Today: Researchers Uncover a Genetic Basis for Different Social Behaviors in Wasps
4. Wyeth Applauds Six Countries Across Europe, and the Middle East, That Recently Announced the Inclusion of the 7-Valent Pneumococcal Conjugate Vaccine (PCV7) in Their Immunization Schedules
5. PRoFESS(R) Results Announced at XVII European Stroke Conference
6. Study Results of GAMMAGARD S/D and GAMMAGARD LIQUID in Patients with Mild-to-Moderate Alzheimers Disease Announced
7. Senesco Expands on Recently Announced Preclinical Pancreatic Islet Data
8. Results of TRIUMPH-1 Trial of Viveta in Pulmonary Arterial Hypertension to Be Announced Before Market Open on Thursday, November 1, 2007
9. ESBATech Raises Additional CHF 23M (USD 22M), Extending Series B Venture Financing
10. Celator Pharmaceuticals Raises Series C Financing in Excess of $22.5 Million
11. Light Sciences Oncology Raises $40.1 Million in Series C Financing
Post Your Comments:
(Date:11/30/2015)... , Nov. 30, 2015   Nuance Communications, Inc. ... National Decision Support Company (NDSC) today jointly announced ... collaboration capabilities that utilize the American College of Radiology,s ... provider organizations to comply with current and emerging ... --> By combining clinical decision support, ...
(Date:11/30/2015)... Booth #4303 – The Imaging Components business of ... broader array of products in a new booth (#4303) at ... North America in Chicago ... X-ray components "At the Heart of Imaging." Products will include ... Varian,s Claymount brand, and computer-aided diagnostic software from MeVis as ...
(Date:11/30/2015)... 30, 2015  Hanger, Inc. (NYSE: HGR ) ... the terms of its previously announced consent solicitation (as ... $200,000,000 aggregate principal amount 7⅛% Senior Notes due 2018 ... consent fees payable pursuant to the Consent Solicitation, (ii) ... (iii) the expiration date of the Consent Solicitation.    ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... 30, 2015 , ... An inventor from Charlottesville, Va., is concerned about the ... had high blood pressure due to loud noises," she said, "so I decided that ... pollution as well as radio waves and microwaves." , The baby BABY MUFF prevents ...
(Date:11/30/2015)... ... November 30, 2015 , ... In an interview with Andy Mitchell of Peconic ... on Long Island’s east end. During the broadcast, entitled “Eyes: the Window to the ... glaucoma and cataracts, and how a visit with his grandmother to her physician put ...
(Date:11/30/2015)... ... November 30, 2015 , ... Since its inception, Seniors ... independent living, assisted living and all other retirement options. Support for issues surrounding ... research remains a top priority. , So it’s no surprise that every ...
(Date:11/30/2015)... ... November 30, 2015 , ... Holcomb – Kreithen Plastic ... surgery practices in Florida, is proud to announce that Dr. Joshua Kreithen, one ... Ethicon Inc., a Johnson & Johnson Company. , Ethicon is a global medical ...
(Date:11/30/2015)... ... November 30, 2015 , ... Sikka Software announced today that they are showcasing ... dentists to make complex business decisions by providing the tools and information they need ... survey with 10 procedures customized by zip code. , The Sikka Software Ecosystem ...
Breaking Medicine News(10 mins):